Promoting proangiogenic pathways, such as VEGFA, a key regulator of vascular growth and therapeutic angiogenesis, increases vascular density and perfusion, offering therapeutic potential against diseases characterized by impaired blood flow, including peripheral artery disease, ischemic heart disease, and ischemic stroke (45, 60, 61). This evidence concerns the gene VEGFA and coronary artery disorder.